Brennan Katherine sold $225K of MRSH

Brennan Katherine (SVP and General Counsel) sold 1,197 shares of MARSH & MCLENNAN COMPANIES, INC. (MRSH) at $187.90 ($0.22M total) on 2026-09-02.

Original reporting
SEC EDGAR · Brennan Katherine
Published Sep 3, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 7:07 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$MRSH
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

Low
01

Why it matters

Impact Analysis

02

Market read

Routine insider sale with limited market relevance.

03

What to watch

No material impact on share price expected given the small size.

Relevance 4/10Novelty 4/10Timing: post‑market 2026‑09‑02

Background

SEC Form 4 filing discloses a 1,197‑share sale by SVP/General Counsel.

Market effects

none

none

none

Counterpoint

The sale may be routine and not indicative of insider concern.

Key entities

  • Marsh & McLennan Companies, Inc.

    Issuer of the Form 4.

  • Brennan Katherine

    SVP and General Counsel who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

MedAI 8/10

Marsh McLennan Agency to acquire century-old Iowa broker Accel Group

Marsh McLennan Agency (MMA) will acquire Accel Group, a privately held Iowa-based insurance broker founded in 1936, with seven offices and 130+ employees. Accel’s services include commercial and personal insurance, employee benefits, agribusiness coverage, and wealth and retirement advisory. MMA said the deal expands rural and agribusiness capacity, following similar regional acquisitions.

$MRSHMed

Marsh & McLennan Companies Q2 Earnings Call Highlights

Marsh & McLennan (NYSE:MRSH) reported Q2 results and discussed market conditions on its earnings call. Consulting revenue rose 10% to $2.6B, with adjusted operating income up 11% to $533M. Mercer revenue was $1.6B. Marsh Global Insurance Market Index showed primary commercial rates down 6% in Q2. The company ended with $20.6B debt and $1.7B cash, and expects $5.5B capital deployment in 2026.

$MRSHMed

Marsh (NYSE:MRSH) Exceeds Q2 CY2026 Expectations

Marsh (NYSE:MRSH) reported Q2 CY2026 results. Revenue rose 6.2% year on year to $7.40 billion, exceeding Wall Street’s estimate by 1.8%, and non-GAAP EPS was $2.96, 2.3% above consensus. Adjusted operating margin was 26.9%. Analysts expect revenue growth of 4.2% and full-year EPS to rise from $10.22 to $10.90.

$MRSHMed

MARSH & MCLENNAN COMPANIES, INC. (MRSH): Results of Operations and Financial Condition

MARSH & MCLENNAN COMPANIES, INC. (MRSH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mmc2q2026ex991newsrelease.htm PRESS RELEASE JUNE 30, 2026 Document Marsh 212 345 5000 www.corporate.marsh.com News release Exhibit 99.1 Marsh reports second quarter 2026 results • Revenue Growth of 6%; Underlying Revenue Growth of 5% • GAAP Operating Income Increases 4%